Pierce R C, Born B, Adams M, Kalivas P W
Alcohol and Drug Abuse Program, Washington State University, Pullman, USA.
J Pharmacol Exp Ther. 1996 Jul;278(1):384-92.
To assess the role of dopamine receptor subtypes in the initiation of behavioral sensitization to cocaine, the partial D1 agonist SKF-38393 (0.01-1.0 microgram/side), the D2/3 agonist quinpirole (0.1-1.0 microgram/side) or saline was infused once daily over 3 days into either the ventral tegmental area (VTA) or the nucleus accumbens shell. Relative to saline controls, intra-VTA SKF-38393 administration did not influence behavior during the treatment regimen, whereas the higher dose of quinpirole produced a significant suppression of locomotor activity after the third daily administration. Infusion of 1.0 microgram/side SKF-38393 into the nucleus accumbens shell produced marked behavioral hyperactivity after both the first and last daily infusions, with no significant difference between the behavioral responses on these days. In contrast, quinpirole did not influence behavior after its infusion into the nucleus accumbens shell. Two weeks after the last daily intracranial drug infusion, all animals were administered cocaine (15 mg/kg, i.p.) and behavioral activity was monitored. The repeated administration of SKF-38393 into the VTA resulted in sensitization to the locomotor-activating effects of cocaine. No other drug pretreatment influenced the cocaine-induced behavioral response. To determine whether repeated D1 agonist administration influenced dopamine release in the nucleus accumbens shell, in vivo microdialysis was performed in this structure after three daily intra-VTA infusions of saline or 0.1 microgram/side SKF-38393. The increase in dopamine levels in the nucleus accumbens shell induced by cocaine was significantly greater among rats pretreated with repeated SKF-38393 administration. Taken together, these results indicate that the repeated intra-VTA administration of a D1 agonist mimics the sensitization process produced by repeated cocaine administration.
为了评估多巴胺受体亚型在对可卡因行为敏化起始过程中的作用,将部分D1激动剂SKF-38393(0.01-1.0微克/侧)、D2/3激动剂喹吡罗(0.1-1.0微克/侧)或生理盐水在3天内每天一次注入腹侧被盖区(VTA)或伏隔核壳。相对于生理盐水对照组,在治疗期间向VTA内注射SKF-38393不影响行为,而较高剂量的喹吡罗在每日第三次给药后显著抑制运动活性。向伏隔核壳内注射1.0微克/侧的SKF-38393在首次和末次每日注射后均产生明显的行为多动,这两天的行为反应无显著差异。相比之下,喹吡罗注入伏隔核壳后不影响行为。在最后一次每日颅内给药两周后,所有动物均给予可卡因(15毫克/千克,腹腔注射)并监测行为活性。向VTA重复注射SKF-38393导致对可卡因的运动激活作用产生敏化。没有其他药物预处理影响可卡因诱导的行为反应。为了确定重复给予D1激动剂是否影响伏隔核壳内的多巴胺释放,在每日3次向VTA内注射生理盐水或0.1微克/侧SKF-38393后,在该结构中进行了体内微透析。在重复给予SKF-38393预处理的大鼠中,可卡因诱导的伏隔核壳内多巴胺水平升高显著更大。综上所述,这些结果表明,向VTA重复注射D1激动剂模拟了重复给予可卡因所产生的敏化过程。